Patent Battles Seek OMB Nod for Paperwork Continuity
Published Date: 8/13/2025
Notice
Summary
The USPTO is asking for approval to keep collecting info about patent reviews and disputes, making sure the process stays smooth and fair. This affects inventors and companies involved in patent fights, with no new fees or big changes, just a chance to comment by the deadline. They’re keeping things clear and easy while checking in with the public to reduce paperwork headaches.
No Economic Impacts Identified for this Document
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-17524, Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; Patent Trial and Appeal Board (PTAB) Appeals
The United States Patent and Trademark Office (hereafter "USPTO" or "Agency") will submit the following information collection request to the Office of Management and Budget (OMB) for review and clearance in accordance with the Paperwork Reduction Act of 1995, on or after the date of publication of this notice. The USPTO invites comments on the information collection renewal of 0651-0063, which helps the USPTO assess the impact of its information collection requirements and minimize the reporting burden to the public. Public comments were previously requested via the Federal Register on April 20, 2026, during a 60-day comment period (91 FR 20986). This notice allows for an additional 30 days for public comments.
2026-17525, Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; Substantive Submissions Made During the Prosecution of the Trademark Application
The United States Patent and Trademark Office (hereafter "USPTO" or "Agency"), as required by the Paperwork Reduction Act of 1995, invites comments on the extension and revision of an existing information collection: 0651-0054 (Substantive Submissions Made During the Prosecution of the Trademark Application). The purpose of this notice is to allow 60 days for public comments preceding submission of the information collection to the Office of Management and Budget (OMB).
2026-16744, Request for Comments on Community Outreach Office Locations in the Southwest States
The USPTO wants your ideas on where to open new community outreach offices in the Southwest states like Arizona and Texas. These offices will help inventors, small businesses, and students get better support with patents. Share your thoughts by September 16, 2026, so the USPTO can pick the best spots and keep innovation booming without extra costs to you!
2026-16315, Administrative Updates to the General Requirements Bulletin for Admission to the Examination for Registration To Practice in Patent Cases Before the United States Patent and Trademark Office
Starting August 11, 2026, the USPTO is upgrading Biomedical Science degrees from Category B to Category A for patent bar eligibility. This means more people with this degree can now take the patent exam and become patent practitioners. No extra fees or delays—just a smoother path for those with the right science background to join the patent world!
2026-14939, Grant of Interim Extension of the Term of U.S. Patent No. 8,877,798; Centanafadine Hydrochloride
Otsuka America Pharmaceutical got a one-year extra patent life for their drug centanafadine hydrochloride because the FDA review is still going on. This means their patent, which was set to expire on July 25, 2026, now lasts until July 25, 2027. This extension helps Otsuka keep exclusive rights to their drug a bit longer while waiting for final FDA approval.
2026-14941, Grant of Interim Extension of the Term of U.S. Patent No. 8,461,196; Centanafadine Hydrochloride
Otsuka America Pharmaceutical got a one-year extra patent life for their drug centanafadine hydrochloride because the FDA review is still going on. This means they keep exclusive rights to the drug until July 25, 2027, giving them more time to sell it without competition. This extension helps the company protect their investment while the drug gets final approval.
Previous / Next Documents
Previous: 2025-15360, Proposed Reinstatement of Terminated Oil and Gas Leases in Las Animas and Weld Counties, CO
Three Colorado companies asked to bring back their oil and gas leases in Las Animas and Weld Counties after they were ended. They paid all the fees they owed, and the government agrees to reinstate the leases since everything checks out with the rules and plans. This means drilling and energy work can continue without delay, keeping business moving and money flowing.
Next: 2025-15362, Sabine Pass Liquefaction, L.L.C.; Sabine Pass Liquefaction Stage V, L.L.C.; Sabine Crossing, L.L.C.; Cheniere Creole Trail Pipeline, L.P.; Notice of Intent To Prepare an Environmental Impact Statement for the Proposed Sabine Pass Stage 5 Expansion Project, Request for Comments on Environmental Issues, and Schedule for Environmental Review
Sabine Pass Liquefaction and partners want to expand their natural gas facilities and pipelines in parts of Louisiana and Texas. The government is getting ready to study how this project might affect the environment and wants your thoughts on it. This review will help decide if the expansion is a good idea and when it can move forward.